Cargando…
Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy
Background: Non-infectious uveitis represents a leading cause of visual impairment, and inflammation control represents a major priority in tackling visual acuity loss due to complications such as macular edema; different immunomodulatory drugs are currently being used, including anti-TNF-alpha Adal...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074084/ https://www.ncbi.nlm.nih.gov/pubmed/32069898 http://dx.doi.org/10.3390/jcm9020510 |
_version_ | 1783506758630637568 |
---|---|
author | Pirani, Vittorio Pelliccioni, Paolo De Turris, Serena Rosati, Alessandro Franceschi, Alessandro Pasanisi, Pierangelo Gesuita, Rosaria Nicolai, Michele Mariotti, Cesare |
author_facet | Pirani, Vittorio Pelliccioni, Paolo De Turris, Serena Rosati, Alessandro Franceschi, Alessandro Pasanisi, Pierangelo Gesuita, Rosaria Nicolai, Michele Mariotti, Cesare |
author_sort | Pirani, Vittorio |
collection | PubMed |
description | Background: Non-infectious uveitis represents a leading cause of visual impairment, and inflammation control represents a major priority in tackling visual acuity loss due to complications such as macular edema; different immunomodulatory drugs are currently being used, including anti-TNF-alpha Adalimumab. Methods: This was a monocentric observational study of 18 eyes of 18 patients with non-infectious uveitis treated with Adalimumab. The primary endpoint was the control of ocular inflammation. The secondary endpoints included the study of macular and choroidal thickness and architecture, visual acuity, changes in other treatments, and adverse effects. Results: Ocular inflammation was controlled at 12 months for 83.3% of patients. Central macular thickness improved from a median of 229.75 µm at baseline to 213 µm at 12 months, while choroidal thickness decreased by 11.54% at the end of the follow-up. A reduction of vasculitis on fluorescein angiography and of hyperreflective spots on optical coherence tomography was noted. Visual acuity also improved from 0.51 (logMAR) before treatment to 0.24 at more than 12 months (p = 0.01). A total of 11.1% of patients experienced side effects. Conclusion: Our study confirms the efficacy of adalimumab for the control of ocular inflammation, visual acuity preservation, and for corticosteroid sparing. |
format | Online Article Text |
id | pubmed-7074084 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70740842020-03-19 Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy Pirani, Vittorio Pelliccioni, Paolo De Turris, Serena Rosati, Alessandro Franceschi, Alessandro Pasanisi, Pierangelo Gesuita, Rosaria Nicolai, Michele Mariotti, Cesare J Clin Med Article Background: Non-infectious uveitis represents a leading cause of visual impairment, and inflammation control represents a major priority in tackling visual acuity loss due to complications such as macular edema; different immunomodulatory drugs are currently being used, including anti-TNF-alpha Adalimumab. Methods: This was a monocentric observational study of 18 eyes of 18 patients with non-infectious uveitis treated with Adalimumab. The primary endpoint was the control of ocular inflammation. The secondary endpoints included the study of macular and choroidal thickness and architecture, visual acuity, changes in other treatments, and adverse effects. Results: Ocular inflammation was controlled at 12 months for 83.3% of patients. Central macular thickness improved from a median of 229.75 µm at baseline to 213 µm at 12 months, while choroidal thickness decreased by 11.54% at the end of the follow-up. A reduction of vasculitis on fluorescein angiography and of hyperreflective spots on optical coherence tomography was noted. Visual acuity also improved from 0.51 (logMAR) before treatment to 0.24 at more than 12 months (p = 0.01). A total of 11.1% of patients experienced side effects. Conclusion: Our study confirms the efficacy of adalimumab for the control of ocular inflammation, visual acuity preservation, and for corticosteroid sparing. MDPI 2020-02-13 /pmc/articles/PMC7074084/ /pubmed/32069898 http://dx.doi.org/10.3390/jcm9020510 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pirani, Vittorio Pelliccioni, Paolo De Turris, Serena Rosati, Alessandro Franceschi, Alessandro Pasanisi, Pierangelo Gesuita, Rosaria Nicolai, Michele Mariotti, Cesare Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy |
title | Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy |
title_full | Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy |
title_fullStr | Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy |
title_full_unstemmed | Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy |
title_short | Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy |
title_sort | intraocular inflammation control and changes in retinal and choroidal architecture in refractory non-infectious uveitis patients after adalimumab therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074084/ https://www.ncbi.nlm.nih.gov/pubmed/32069898 http://dx.doi.org/10.3390/jcm9020510 |
work_keys_str_mv | AT piranivittorio intraocularinflammationcontrolandchangesinretinalandchoroidalarchitectureinrefractorynoninfectiousuveitispatientsafteradalimumabtherapy AT pelliccionipaolo intraocularinflammationcontrolandchangesinretinalandchoroidalarchitectureinrefractorynoninfectiousuveitispatientsafteradalimumabtherapy AT deturrisserena intraocularinflammationcontrolandchangesinretinalandchoroidalarchitectureinrefractorynoninfectiousuveitispatientsafteradalimumabtherapy AT rosatialessandro intraocularinflammationcontrolandchangesinretinalandchoroidalarchitectureinrefractorynoninfectiousuveitispatientsafteradalimumabtherapy AT franceschialessandro intraocularinflammationcontrolandchangesinretinalandchoroidalarchitectureinrefractorynoninfectiousuveitispatientsafteradalimumabtherapy AT pasanisipierangelo intraocularinflammationcontrolandchangesinretinalandchoroidalarchitectureinrefractorynoninfectiousuveitispatientsafteradalimumabtherapy AT gesuitarosaria intraocularinflammationcontrolandchangesinretinalandchoroidalarchitectureinrefractorynoninfectiousuveitispatientsafteradalimumabtherapy AT nicolaimichele intraocularinflammationcontrolandchangesinretinalandchoroidalarchitectureinrefractorynoninfectiousuveitispatientsafteradalimumabtherapy AT mariotticesare intraocularinflammationcontrolandchangesinretinalandchoroidalarchitectureinrefractorynoninfectiousuveitispatientsafteradalimumabtherapy |